OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.26 SEK | +0.31% |
|
+5.59% | +24.58% |
| May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OREXO AB | Specialty & Advanced Pharmaceuticals | +0.31% | +5.59% | +24.58% | +83.43% | -72.83% | 61.23M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ORX Stock
- Charts Orexo AB
- Comparison Chart